Loading organizations...
bioMérieux is a French multinational biotechnology company, a global leader in in vitro diagnostics. Headquartered in Marcy-l'Étoile, France, the firm develops diagnostic solutions providing information for patient care, encompassing pathogen detection and analysis of health markers. Its offerings support clinical and industrial applications.
The company's legacy traces to the 19th century with Marcel Mérieux, a pioneering student of Louis Pasteur, whose foundational work set the stage. Building upon this heritage, bioMérieux was formally established in 1963, driven by the insight that advanced in vitro diagnostic tools were essential for modern healthcare and disease management.
bioMérieux's diagnostic products and services serve laboratories, hospitals, and industrial partners globally, assisting in medical decision-making, disease prevention, and ensuring product safety. The company's overarching vision centers on continuously innovating to enhance public health worldwide through reliable, actionable diagnostic insights.
Key people at bioMérieux.
Key people at bioMérieux.
bioMérieux has 1 tracked investment across 1 company. The latest tracked deal is $4.2M Seed in Allergen Alert in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 5, 2026 | Allergen Alert | $4.2M Seed | Metropolitan Industrial Seed Fund | — |